Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Clinical Trial 41298

Birmingham, AL 35209


Study Summary:

This clinical trial is investigating an oral medication (GB001) that is added to your standard asthma treatment. This medication is considered to be a DP2 antagonist, which means that it's designed to target inflammation of the lungs, hopefully leading to less flaring of asthma, and less steriod use. Study lasts for 34 weeks and there are 9 office visits. Treatment arms include the following.

  • 20mg dose of GB001
  • 40mg dose of GB001
  • 60mg dose of GB001
  • Placebo (looks like study medication but no active ingredients)

 


Qualified Participants Must:

• Be 19 years or older
• Use of high dose inhaled corticosteriod plus controller
• Must have had at least one flare up of asthma in past 12 months that required steriods at physician's office
• No use of monoclonal antibodies (Xolair, Nucala, Fasenra, Cinqair)
• Non-smoker or smoking history of less than 10 pack years


Qualified Participants May Receive:

  • Study medicaiton at no cost
  • Study related care from research staff and physicians at no cost
  • Compensated $114 per each completed office visit ($200 for Visit 2)


Research Site Profile

View Clinic Profile


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.